Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

VISION: Defining Biomarkers of Chemotherapy & Immunotherapy Response and Validation of the Breast Cancer Therapeutic Response Predictive Algorithm for Early Triple Negative Breast Cancers

NCT06409221 is registered in ClinicalTrials.gov with Concr as lead sponsor.

NCT NCT06409221
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06409221 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
VISION: Defining Biomarkers of Chemotherapy & Immunotherapy Response and Validation of the Breast Cancer Therapeutic Response Predictive Algorithm for Early Triple Negative Breast Cancers
Lead sponsor
Concr
Phase
Observational
Overall status
Unknown status
Start date
May 1, 2024
Completion date
December 31, 2025
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, breast, early-stage breast cancer, triple negative breast cancer